PT  - JOURNAL ARTICLE
AU  - Tene, Lilac
AU  - Chodick, Gabriel
AU  - Fallach, Noga
AU  - Ansari, Wajeeha
AU  - Distelman-Menachem, Tal
AU  - Maor, Yasmin
TI  - Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel
AID  - 10.1101/2022.05.02.22274586
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.02.22274586
4099  - http://medrxiv.org/content/early/2022/05/03/2022.05.02.22274586.short
4100  - http://medrxiv.org/content/early/2022/05/03/2022.05.02.22274586.full
AB  - Title Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in IsraelObjective The objective of this feasibility study was to assess the number of patients that could be included in a future Real World Evidence study, which would be designed to explore the impact of Paxlovid (nirmatrelvir/ritonavir) on patient outcomes and healthcare resource utilization (HCRU). We also intend to assess the comparability of the patients who were treated with Paxlovid versus patients who did not receive the treatment, either because they declined any COVID-19 treatment or were diagnosed with COVID-19 prior to Paxlovid availability.Methods This retrospective observational secondary data study used data from the Maccabi Healthcare Services database during the identification period of June 1, 2021, to February 28, 2022. The study population included patients with at least one positive SARS-CoV-2 RT-PCR test, or a formal rapid antigen test for SARS-CoV-2, during the identification period, the date of which also served as the COVID-19 diagnosis date. We then divided the study population into the following cohorts: Pre-Paxlovid Time Period and Paxlovid Time Period, which was further split into Paxlovid Treated and Paxlovid Untreated.Results Application of inclusion and exclusion criteria to the study population rendered 20,284 patients in the Pre-Paxlovid Time Period cohort and 5,542 in the Paxlovid Time Period cohort that were eligible to receive Paxlovid. This resulted in 3,714 in the Paxlovid Treated and 1,810 in the Paxlovid Untreated cohorts.Conclusions This RWE feasibility study of patients with a positive test for COVID-19 between June 1, 2021 to February 28, 2022 illustrates potential comparability between cohorts, as described by their demographics and characteristics.Competing Interest StatementThis study was conducted as a collaboration between Maccabi Healthcare Services and Pfizer. Maccabi Healthcare Services is the study sponsor.  Funding StatementThis study was funded by Pfizer Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of Maccabi Healthcare Services gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript